Skip to main content

Advertisement

Table 3 Sensitivity of the duration (time to achieve pOTTIS) and relative total cost of annual ivermectin (aCDTI), biannual ivermectin (bCDTI) and annual moxidectin (aCDTM) treatment programmes to the percentage of therapeutic coverage and systematic non-compliance

From: The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data

Baseline endemicity level (microfilarial prevalence) Systematic non-compliance 80% overall therapeutic coverage 60% overall therapeutic coverage
Projected duration, in years, of treatment programme (relative cost, in percent) Projected duration, in years, of treatment programme (relative cost, in percent)
aCDTI bCDTI (ǂ) aCDTM (ǂ,†) aCDTI bCDTI (ǂ) aCDTM (ǂ,†)
Mesoendemic (40%) 0.1% 17 11 (113%) 11 (71%, 63%) 23 14 (108%) 15 (75%, 70%)
  2.0% 18 13 (124%) 13 (78%, 63%) 24 15 (133%) 16 (75%, 66%)
  5.0% 20 16 (136%) 16 (85%, 63%) 26 18 (124%) 19 (80%, 65%)
Hyperendemic (60%) 0.1% 25 16 (116%) 17 (76%, 66%) 37 19 (104%) 21 (70%, 67%)
  2.0% 28 19 (123%) 20 (80%, 65%) 42 22 (108%) 24 (72%, 66%)
  5.0% 32 24 (133%) 24 (83%, 63%) 49 28 (119%) 29 (76%, 64%)
Highly hyperendemic (80%) 0.1% NA 26 (112%) 26 (70%, 63%) NA 38 (140%) 46 (96%, 69%)
  2.0% NA 40 (144%) 43 (80%, 65%) NA NA (160%) NA (100%, 63%)
  5.0% NA NA (160%) NA (100%, 63%) NA NA (160%) NA (100%, 63%)
  1. ǂPercentage cost relative to aCDTI. Percentage cost relative to bCDTI. NA: Operational thresholds for treatment interruption not attained within the 50-year time horizon (and percentage of costs calculated based on costs of 50 years of treatment). Modelling assumptions are as in the legend of Table 2.